Table 1:
Baseline characteristics by final long-term PPI dose regimen in patients with endoscopic follow-up (n = 50)
| Final dose unchanged (n = 14) |
Final dose increased (n = 3) |
Final dose lowered (n = 22) |
Final dose re-increased (n = 11) |
p* | |
|---|---|---|---|---|---|
| Age (mean years ± SD) | 47.7 ± 14.2 | 40.1 ± 9.0 | 46.5 ± 14.9 | 40.7 ± 12.5 | 0.55 |
| Male (n, %) | 9 (64) | 2 (67) | 10 (45) | 8 (73) | 0.44 |
| White (n, %) | 12 (86) | 3 (100) | 21 (95) | 10 (91) | 0.71 |
| Symptoms (n, %) | |||||
| Dysphagia | 14 (100) | 3 (100) | 22 (100) | 11 (100) | -- |
| Heartburn | 7 (50) | 1 (33) | 4 (18) | 1 (9) | 0.09 |
| Abdominal pain | 3 (21) | 1 (33) | 3 (14) | 0 (0) | 0.34 |
| Nausea/vomiting | 3 (21) | 1 (33) | 2 (14) | 0 (0) | 0.34 |
| Atopy (n, %) | |||||
| Seasonal allergies | 7 (50) | 2 (67) | 16 (73) | 4 (36) | 0.21 |
| Asthma | 5 (36) | 2 (67) | 7 (32) | 1 (9) | 0.22 |
| Food allergies | 2 (14) | 2 (67) | 5 (23) | 1 (9) | 0.15 |
| Eczema | |||||
| Endoscopic findings (n, %) | |||||
| Rings | 10 (71) | 0 (0) | 12 (55) | 10 (91) | 0.02 |
| Stricture | 6 (43) | 1 (33) | 7 (32) | 4 (36) | 0.93 |
| Narrowing | 1 (7) | 0 (0) | 3 (14) | 2 (18) | 0.76 |
| Furrows | 7 (50) | 1 (33) | 15 (68) | 8 (72) | 0.42 |
| Exudates | 7 (50) | 0 (0) | 8 (36) | 6 (55) | 0.32 |
| Edema | 4 (29) | 0 (0) | 9 (41) | 4 (36) | 0.53 |
| Dilation performed | 5 (34) | 2 (67) | 11 (50) | 4 (37) | 0.66 |
| Peak eosinophil counts (mean eos/hpf ± SD) | |||||
| Pre-PPI treatment | 65.2 ± 41.0 | 83.3 ± 93.6 | 61.1 ± 38.3 | 71.7 ± 72.8 | 0.88 |
| Post-PPI treatment | 4.7 ± 5.1 | 9.8 ± 4.0 | 5.5 ± 4.4 | 4.1 ± 4.3 | 0.28 |
| Mean follow-up time (years ± SD) | 2.4 ± 1.8 | 2.8 ± 3.1 | 2.8 ± 1.9 | 6.8 ± 3.6 | < 0.001 |
| PPI medication type (n, %) | 0.12 | ||||
| Dexlansoprazole | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| Mean daily dose† (mg ± SD) | -- | -- | -- | -- | |
| Esomeprazole | 1 (7) | 0 (0) | 4 (18) | 2 (18) | |
| Mean daily dose (mg ± SD) | 40 ± 0 | -- | 70 ± 20 | 80 ± 0 | |
| Lansoprazole | 2 (14) | 0 (0) | 1 (5) | 2 (18) | |
| Mean daily dose (mg ± SD) | 60 ± 0 | -- | 60 ± 0 | 60 ± 0 | |
| Omeprazole | 7 (50) | 2 (67) | 17 (77) | 7 (64) | |
| Mean daily dose (mg ± SD) | 40 ± 0 | 40 ± 0 | 44.7 ± 0 | 40 ± 0 | |
| Pantoprazole | 4 (29) | 1 (33) | 0 (0) | 0 (0) | |
| Mean daily dose (mg ± SD) | 60 ± 23.1 | 40 ± 0 | -- | -- | |
| PPI dose category (n, %)‡ | 0.08 | ||||
| Single/standard | 2 (14) | 1 (33) | 0 (0) | 0 (0) | |
| Double | 12 (86) | 2(67) | 17 (77) | 9 (82) | |
| Quadruple | 0 (0) | 0 (0) | 5 (23) | 2 (18) |
*
Means compared with means compared with ANOVA, proportions compared with Chi squared
†
There were no statistically significant differences between the mean doses for any of the PPIs
‡
Categorization based one standard doses as follows: omeprazole 20 mg, pantoprazole 40mg, esomeprazole 20 mg, lansoprazole 30 mg, with double and quadruple calculated accordingly; no patients received rabeprazole.